Business Wire

AdvanCell Closes A$18M Series B Funding Led by Morningside

Share

AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 million Series B financing round led by Morningside.

Andrew Adamovich, CEO and Founder of AdvanCell noted, “We are very pleased with our progress to date and delighted that we will continue our rapid growth with the support of our shareholders. We have had a long-term relationship with our lead investor, Morningside, and are excited to come closer still to our goal to 'Change the Course of Cancer Treatment.'”

Targeted Alpha Therapies represent the most exciting opportunity to treat currently untreatable cancers. The technology harnesses the natural decay and radiochemical properties of certain elements, in combination with specific targeting molecules, to selectively deliver cell-killing radiation to the tumour cell. AdvanCell believes this precise and powerful treatment will rapidly become a leading pillar of cancer treatment, providing treatments for diseases for which there are currently no effective options. Targeted Alpha Therapies demonstrate incredible efficacy, however widespread adoption and large commercial product launches require a scalable and reliable global isotope supply. AdvanCell was established to solve this problem.

AdvanCell’s ability to produce isotope on-demand and at scale, and its in-house radiopharmaceutical manufacturing expertise positions AdvanCell to play a leading role in this rapidly growing market. With additional support from NSW Health Medical Devices Fund and the Federal government’s Research & Development Tax Incentive, AdvanCell has developed a world-first scalable manufacturing platform to produce alpha-emitting isotopes for research, pre-clinical and clinical use and to advance its own and its partners' radiopharmaceutical products.

Anthony Aiudi from Morningside commented, “AdvanCell is leveraging its ability to make alpha isotopes at scale and in clinically useful amounts along with its radiochemistry expertise, to develop an exciting portfolio of Targeted Alpha Therapies. Targeted Alpha Therapies hold incredible promise however their development has been hamstrung by a lack of radioisotope supply. Together with the team at AdvanCell, we look forward to writing a new chapter in oncology, to target large patient populations with significant unmet needs.”

Mr Aiudi has been appointed to the Board of AdvanCell, joining Mr Adamovich, Bill Ferris AC, co-founder of CPE Capital, Adrian “Adi” Patterson, former Australian Nuclear Science and Technology Organisation (ANSTO) CEO and Kevin Cameron, CEO of Ionetix.

Bill Ferris AC, Chair remarked, “Our executive team has articulated a credible pre-clinical and clinical pathway for the delivery of the Company’s novel Targeted Alpha Therapies. Having successfully developed the manufacturing platform essential for the reliable and scalable supply of isotopes, the Company is on schedule with its pre-clinical work and is now moving into first-in-human trials. AdvanCell is on track to become a leading radiopharmaceutical company with a platform technology enabling novel cancer treatments.”

About AdvanCell

AdvanCell is a radiopharmaceutical company developing next-generation cancer treatment. AdvanCell’s Targeted Alpha Therapies are powered by a platform technology – a world-first alpha isotope generator that addresses the greatest unmet need in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell has a world-class team and is honoured to be advised by an outstanding Board of Directors and Scientific Advisory Board. For more information visit www.advancell.com.au

About Morningside

Founded in 1986 by the Chan family, Morningside is a technology and life science venture investment firm. With offices in Boston, Shanghai and London, the firm invests globally. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. Morningside partners with academic founders and entrepreneurs to build world-class companies that want to markedly improve the current state of medicine today and ultimately, the lives of patients. In addition to its investment activities, Morningside Ventures is strongly committed to social responsibility. For more information visit www.morningside.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

contact@advancell.com.au

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

O-RAN ALLIANCE Announces Key Topics at the Open RAN Summit at Fyuz, Global PlugFest Fall 2022 and a New Set of O-RAN Demos26.9.2022 19:45:00 CEST | Press release

O-RAN ALLIANCE: Key topics at the Open RAN Summit @ Fyuz 2022 brought by the O-RAN ALLIANCE The Open RAN Summit @ Fyuz, powered by O-RAN ALLIANCE and Telecom Infra Project, will take place in Madrid on October 25-26, 2022. As a main partner of the event, O-RAN ALLIANCE brings key topics to the agenda and invites utmost erudite speakers. Join the event to get the latest news and views on: O-RAN ALLIANCE and TIP cooperation Established operators worldwide showcasing how they are overcoming Open RAN challenges and moving forward with deployments Open RAN cloudification options and realities Achievements and challenges on the open RAN supply side, along with insights into value chain evolution Rich variety of Open RAN deployment paths tailored to meet diverse operator’s needs How the testing and integration work is critical to making Open RAN a success What’s behind the hype of the RAN Intelligent Controllers and how an empowered ecosystem delivers customized operator value And many more i

Boomi Appoints Mark Fields to Its Board of Directors26.9.2022 18:00:00 CEST | Press release

Boomi™, the intelligent connectivity and automation leader, today announced the appointment of former CEO of Ford Motor Company Mark Fields as an independent, non-executive member of its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005019/en/ Boomi Appoints Mark Fields to Board of Directors (Graphic: Business Wire) “As Boomi continues its rapid growth, we’re excited to attract sought-after leaders to join our mission to make the world a better place by connecting everyone to everything, anywhere,” said David Meredith, CEO at Boomi. “Mark’s exceptional track record as a leader, advisor and visionary — coupled with our award-winning technology and innovation — helps position Boomi to deliver superior outcomes for even more customers.” Mark Fields As former CEO of Ford Motor Company, Fields brings three decades of experience driving innovation and business transformation initiatives across multi-bill

ONWARD Announces Appointment of Vivian Riefberg to Board of Directors26.9.2022 17:30:00 CEST | Press release

ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announced the appointment of Vivian Riefberg as a non-executive member of its Board of Directors. Ms. Riefberg will join the Board immediately and will serve on its Compensation Committee. Her appointment to the Board will be presented for shareholder approval at the next Annual General Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005494/en/ Vivian Riefberg joins the ONWARD Medical Board of Directors (Photo: Business Wire) “Vivian Riefberg is a distinguished expert in health care, government, and strategy. I am excited and honored to welcome her to our Board”, said Dave Marver, Chief Executive Officer. “Vivian brings a rich understanding of the institutions with which we will collaborate to bring our novel therapies to market

ComTech Gold $CGO Becomes the First 100% Gold Backed Token to Receive Shariah Certification in the MENA Region26.9.2022 17:25:00 CEST | Press release

ComTech FZCO receives Shariah Compliance Certification for ComTech Gold Token (CGO), becoming the first in industry to be awarded a Shariah certification for Gold tokenization product in the Region. Shariah certification (Fatwa) was issued by Amanie Advisors Ltd, an entity specialising in field of Shariah-compliant investments and Islamic finance solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005591/en/ ComTech Gold $CGO receives Shariah Certification from Amanie Advisors (Photo: AETOSWire) ComTech FZCO, a Dubai-based company redefining tokenization infrastructure (for real-world assets), started with digitization of Gold powered by XDC Network. ComTech Gold ‘CGO’ is listed on Global Exchanges like LBank, Bitrue. Investors can buy CGO by opening an account with these exchanges. Investors can hold tokens within the exchange wallets or with any of the Internationally accepted wallets like D’cent, Guarda, or th

Actylis Debuts, Signaling the Creation of an Integrated Global Specialty Ingredients Manufacturing and Sourcing Powerhouse26.9.2022 17:00:00 CEST | Press release

Actylis, a leading global manufacturer and sourcing expert of critical raw materials and performance ingredients for the life sciences and specialty chemicals markets, made its debut today. The new company combines Aceto and 10 industry specialists into an integrated global ingredient powerhouse. Actylis (“Ac-till-iss”) is the culmination of an ambitious initiative launched several years ago to address the major unmet need for better and more dependable access to critical raw materials and performance ingredients essential for the manufacture of highly regulated products in key industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005021/en/ To achieve this goal, Actylis has integrated leading specialty ingredient manufacturing and sourcing companies, including A&C, A&C Bio Buffer, Aceto, Biotron Laboratories, Cascade Chemistry, Finar, Inter-Actifs, IsleChem, Pharma Waldhof, Syntor Fine Chemicals and Talus into on

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom